The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena
ConclusionIn our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 “relatively new statements” that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implement ation. (Source: Archives of Osteoporosis)
Source: Archives of Osteoporosis - April 2, 2024 Category: Orthopaedics Source Type: research
The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena
ConclusionIn our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 “relatively new statements” that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implement ation. (Source: Archives of Orthopaedic and Trauma Surgery)
Source: Archives of Orthopaedic and Trauma Surgery - April 2, 2024 Category: Orthopaedics Source Type: research
Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium
ConclusionSequential treatment with romosozumab followed by alendronate was found to be cost-effective compared to alendronate monotherapy and dominant compared to teriparatide followed by alendronate for postmenopausal women with osteoporosis at high risk of fracture in Belgium. (Source: Osteoporosis International)
Source: Osteoporosis International - April 2, 2024 Category: Orthopaedics Source Type: research
Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis
ConclusionAFF was characterised by usually long duration of bisphosphonate use, higher BMD and more acute neck-shaft angle. AFF did not confer significant impairment in mobility or mortality. Nonetheless, further research work is necessary to optimise bone health among patients who develop AFF. (Source: Endocrine)
Source: Endocrine - April 1, 2024 Category: Endocrinology Source Type: research
The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis
ConclusionThe 2023 guidelines for the management and treatment of GIOP was developed through systematic reviews and consensus conferences using the Delphi method. (Source: Journal of Bone and Mineral Metabolism)
Source: Journal of Bone and Mineral Metabolism - March 28, 2024 Category: Orthopaedics Source Type: research
Update on the DVO Guideline 2023 "Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50"-What's new for rheumatology?
Z Rheumatol. 2024 Mar 21. doi: 10.1007/s00393-024-01495-x. Online ahead of print.ABSTRACTIn October 2023, the organization of the German-speaking scientific osteological societies (DVO) published the revised guideline on the "Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50." This review article reflects the new features of the guideline and their relevance in the care of patients with inflammatory rheumatic diseases.A key innovation is the change from the 10-year fracture risk to the 3‑year fracture risk. Basic diagnostics are currently performed without a defined frac...
Source: Zeitschrift fur Rheumatologie - March 21, 2024 Category: Rheumatology Authors: Alexander Pfeil Uwe Lange Source Type: research
Update on the DVO Guideline 2023 "Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50"-What's new for rheumatology?
Z Rheumatol. 2024 Mar 21. doi: 10.1007/s00393-024-01495-x. Online ahead of print.ABSTRACTIn October 2023, the organization of the German-speaking scientific osteological societies (DVO) published the revised guideline on the "Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50." This review article reflects the new features of the guideline and their relevance in the care of patients with inflammatory rheumatic diseases.A key innovation is the change from the 10-year fracture risk to the 3‑year fracture risk. Basic diagnostics are currently performed without a defined frac...
Source: Zeitschrift fur Rheumatologie - March 21, 2024 Category: Rheumatology Authors: Alexander Pfeil Uwe Lange Source Type: research
Update on the DVO Guideline 2023 "Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50"-What's new for rheumatology?
Z Rheumatol. 2024 Mar 21. doi: 10.1007/s00393-024-01495-x. Online ahead of print.ABSTRACTIn October 2023, the organization of the German-speaking scientific osteological societies (DVO) published the revised guideline on the "Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50." This review article reflects the new features of the guideline and their relevance in the care of patients with inflammatory rheumatic diseases.A key innovation is the change from the 10-year fracture risk to the 3‑year fracture risk. Basic diagnostics are currently performed without a defined frac...
Source: Zeitschrift fur Rheumatologie - March 21, 2024 Category: Rheumatology Authors: Alexander Pfeil Uwe Lange Source Type: research
Update on the DVO Guideline 2023 "Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50"-What's new for rheumatology?
Z Rheumatol. 2024 Mar 21. doi: 10.1007/s00393-024-01495-x. Online ahead of print.ABSTRACTIn October 2023, the organization of the German-speaking scientific osteological societies (DVO) published the revised guideline on the "Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50." This review article reflects the new features of the guideline and their relevance in the care of patients with inflammatory rheumatic diseases.A key innovation is the change from the 10-year fracture risk to the 3‑year fracture risk. Basic diagnostics are currently performed without a defined frac...
Source: Zeitschrift fur Rheumatologie - March 21, 2024 Category: Rheumatology Authors: Alexander Pfeil Uwe Lange Source Type: research
Update on the DVO Guideline 2023 "Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50"-What's new for rheumatology?
Z Rheumatol. 2024 Mar 21. doi: 10.1007/s00393-024-01495-x. Online ahead of print.ABSTRACTIn October 2023, the organization of the German-speaking scientific osteological societies (DVO) published the revised guideline on the "Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50." This review article reflects the new features of the guideline and their relevance in the care of patients with inflammatory rheumatic diseases.A key innovation is the change from the 10-year fracture risk to the 3‑year fracture risk. Basic diagnostics are currently performed without a defined frac...
Source: Zeitschrift fur Rheumatologie - March 21, 2024 Category: Rheumatology Authors: Alexander Pfeil Uwe Lange Source Type: research
Comparative analysis of anti-osteoporosis medications in preventing vertebral body fractures after balloon kyphoplasty
ConclusionThe anabolic agents were found to be more effective at reducing the incidence of SVBF (especially distant vertebral fractures) than alendronate. These agents decreased the rate of repeat BKP even after the occurrence of a fracture. Overall, the use of an anabolic agent for the treatment of osteoporosis after BKP is better than the use of alendronate, even when treatment is initiated in the perioperative stage. (Source: Archives of Osteoporosis)
Source: Archives of Osteoporosis - March 21, 2024 Category: Orthopaedics Source Type: research
Comparative analysis of anti-osteoporosis medications in preventing vertebral body fractures after balloon kyphoplasty
ConclusionThe anabolic agents were found to be more effective at reducing the incidence of SVBF (especially distant vertebral fractures) than alendronate. These agents decreased the rate of repeat BKP even after the occurrence of a fracture. Overall, the use of an anabolic agent for the treatment of osteoporosis after BKP is better than the use of alendronate, even when treatment is initiated in the perioperative stage. (Source: Archives of Orthopaedic and Trauma Surgery)
Source: Archives of Orthopaedic and Trauma Surgery - March 21, 2024 Category: Orthopaedics Source Type: research
Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study
CONCLUSIONS: In a diverse real-world setting, prescription of romosozumab for osteoporosis is associated with less adverse CV events when compared to PTH analog therapy.PMID:38482603 | DOI:10.1210/clinem/dgae173 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - March 14, 2024 Category: Endocrinology Authors: Joshua Stokar Auryan Szalat Source Type: research
Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study
CONCLUSIONS: In a diverse real-world setting, prescription of romosozumab for osteoporosis is associated with less adverse CV events when compared to PTH analog therapy.PMID:38482603 | DOI:10.1210/clinem/dgae173 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - March 14, 2024 Category: Endocrinology Authors: Joshua Stokar Auryan Szalat Source Type: research
